Retinoblastoma protein (Rb) is an important regulator of vertebrate cell cycle and development. It functions through a direct interaction with protein factors involved in cell cycle progression and differentiation. In the present study we characterized a novel Rb-associated protein, Cream1, which bound to Rb specifically through a C-terminal region. Cream1 contained 959 amino acid residues and migrated as a protein of approx. 120 kDa on SDS\PAGE. It was a widely expressed nuclear protein with a nuclear localization signal resembling that of the large T antigen of simian virus 40. Its primary sequence was characteristic of five direct repeats that were similar to, but distinct from, those of TFII-I, a multifunctional transcription regulator. Three additional regions were also highly conserved in
INTRODUCTION
Retinoblastoma protein (Rb) was the first identified tumour suppressor [1] . During the cell cycle, Rb functions as one of the key components of the G " checkpoint for the faithful regulation of the rhythm of the cell cycle. Disruption of Rb function might result in tumorigenesis, deregulated apoptosis and certain deficiencies during the developmental process [2] [3] [4] . Transforming proteins of several DNA tumour viruses, including the large T antigen of simian virus 40 (SV40), E1a of adenovirus and E7 of papillomavirus type 16, interact directly with the T-antigenbinding domain of Rb on virus transfection. Such a step is critical for the subsequent transformation of host cells. These interactions lead to the dissociation of Rb-associated cellular factors that are important for cell cycle progression, e.g. E2F-1, to bypass the normal mechanism in which these factors are released after the phosphorylation of Rb by cyclin-dependent kinases in late G " . The cell cycle is therefore deregulated, which is a hallmark of tumour cells. A similar strategy has been adopted by naturally occurring tumour cells. As a result, various mutations impairing Rb function have been found in all retinoblastomas and with varying penetrances in tumours such as osteosarcoma, lung carcinoma and bladder cancer [1] .
Recent studies have unravelled novel functions of Rb in early embryonic development and tissue differentiation. Rb-deficient mice die between embryonic days 14 and 15 with abnormalities Abbreviations used : BD, DNA-binding domain of Gal4 ; Btk, Bruton's tyrosine kinase ; Ccr1-Ccr3, Cream's conserved regions 1-3 ; Cr1-Cr5, Cream1 repeats 1-5 ; EST, expressed sequence tag ; FLAG, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys ; IIF, indrect immunofluorescence ; mAb, monoclonal antibody ; MBP, maltose-binding protein ; NLS, nuclear localization signal ; SIE, c-sis-platelet-derived growth factor-inducible element ; Rb, retinoblastoma protein ; SV40, simian virus 40 ; Tcr1-Tcr3, TFII-I's conserved regions 1-3 ; TnI S , slow-muscle-fibre-specific troponin I ; Tr1-Tr6, TFII-I repeats [1] [2] [3] [4] [5] [6] . 1 To whom correspondence should be addressed (e-mail xlzhu!sunm.shcnc.ac.cn).
The nucleotide sequence data reported will appear in DDBJ, EMBL and GenBank Nucleotide Sequence Databases under the accession number AF089107. both proteins. Cream1 exhibited an activation activity that was attributed to its N-terminal portion when assayed in yeast. Its relationship with the muscle-enhancer-binding protein Mus-TRD1 further suggests a role in regulating gene expression. The structural gene, CREAM1, contained 27 exons and spanned more than 150 kb. It was located at human chromosome 7q11.23 in a region deleted for Williams ' syndrome, a neurodevelopmental disease with multisystem abnormalities, implying its involvement in certain disorders. Taken together, our results suggest that Cream1 might serve as a positive transcription regulator under the control of Rb.
Key words : MusTRD1, nuclear protein, Williams' syndrome.
in neurogenesis and haemopoiesis [3] . Rb is also required for adipogenesis in mouse ; in contrast with its general inhibitory effects in cell cycle control, Rb seems to regulate adipocyte differentiation by activating CCAAT-enhancer-binding proteins (' C\EBPs ') through direct interaction [5] . Moreover, murine skeletal muscle cells are not fully differentiated without functional Rb because differentiated myocytes can re-enter the cell cycle [6, 7] . Rb might exert its function in myogenesis by activating the myogenic transcription factor MyoD [6] . In addition, the stoichiometry of Rb and the transcription repressor HBP1 might also contribute to myoblast differentiation [8] .
TFII-I is a multifunctional transcription regulator. It is initially identified as an initiator-binding factor involved in transcription initiation through initiator sites in TATA-less promoters [9] . TFII-I contains six conserved repeats [10, 11] . Although the physiological roles of the repeats are currently unknown, the presence of helix-loop-helix-like domains implies their potential for binding DNA [10] . TFII-I has been shown to bind distinct DNA sequences. Among them are the initiator sites of adenovirus major late promoter [10] and murine Vβ 5.2 promoter [12] , the Ebox element [10] , and c-sis-platelet-derived growth factor-inducible element (SIE) and serum-responsive element (' SRE ') of the c-fos promoter [11] . There is evidence for at least two independent DNA-binding domains, for the initiator and the E-box element respectively [10] . TFII-I also interacts directly with various transcription factors such as c-myc [13] , USF1 [10] , SRF and Phox1 [11] , and STAT1 and STAT3 [14] . In addition, TFII-I (also named BAP-135) binds to Bruton's tyrosine kinase (Btk), a cytoplasmic tyrosine kinase required for normal B-cell development, and is tyrosine-phosphorylated depending on the activation of Btk [15] . The tyrosine phosphorylation of TFII-I is important for its initiator-dependent transcriptional activity [16] . These intriguing properties suggest that TFII-I might function to co-ordinate the basic transcription machinery and a group of upstream regulatory factors in response to certain signalling pathways. Finally, hemizygosity for TFII-I is associated with Williams' syndrome, a neurodevelopmental disorder [17] .
Our previous work on the identification of Rb-associated proteins has led to the molecular cloning of E2F-1 and other candidate genes [18] . Some of these gene products, including lamin [19, 20] , UBF [21] and mitosin [22] , have been studied further with regard to their relationship with Rb. Here we report the characterization of another candidate, Cream1, a widely expressed nuclear protein of molecular mass 120 kDa. Our results suggest that Cream1 might function as a ubiquitous transcription regulator under the control of Rb. Moreover, the gene for Cream1 is located within a region frequently deleted in patients with Williams' syndrome. This gene might therefore contribute to this multisystem disease.
EXPERIMENTAL cDNA cloning
The original cDNA fragment, Ap-2, was isolated from a HeLa expression cDNA library by using purified Rb as a probe [18] . It was used to screen further for longer cDNA clones. Owing to the low abundance of Cream1 cDNA in the libraries used, the 5h coding sequences were obtained by PCR with plasmid DNA from a placenta cDNA library (Clontech) and the Marathon cDNA from human fetal spleen (Clontech) as templates. PCR fragments were subcloned into pGEM-T Easy Vector (Promega) and selected by Southern blotting. To avoid the possibility that mutations were introduced by PCR, at least three independent clones for each product were sequenced. cDNA fragments with sequences shared by the majority of clones were then selected to construct the full-length cDNA.
Plasmid construction

Plasmids for the expression of FLAG-tagged Cream1 in mammalian cells
To express full-length Cream1 tagged with the FLAG epitope (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys), the NcoI-ScaI restriction fragment (containing nt 6-2893) was ligated into the NheI site of pCEP4F vector [22] to create pFCream1 after fill-in reactions for both fragments with Klenow enzyme. pFAP32 was constructed in a similar way by using the NcoI-ScaI restriction fragment containing nt 762-2893 to express FLAG-Ap32 (containing residues 253-959). pFAP32N was constructed by PCR to express FLAG-Ap32N (containing residues 253-897).
Plasmids for the expression of FLAG-tagged Cream1 in Escherichia coli
To express FLAG-Ap32 in E. coli, pTrc-AP32 was constructed by inserting the 2.1 kb NcoI-XhoI restriction fragment from pFAP32 into pTrcHisA (Invitrogen) cleaved with the same restriction enzymes. To express full-length FLAG-Cream1, the full-length cDNA was ligated in frame into pTrcHisA to create pFLAP2. pFLAP2 was in turn cleaved with PstI and self-ligated to form pFLCream1p to express FLAG-Cream1p (containing residues 1-455).
Plasmids for assays in yeast
The NcoI-ScaI fragment (nt 6-2893) was inserted between the NcoI and SalI (filled in with Klenow) sites of pAS2-1 (Clontech) to express BD-Cream1 (containing residues 1-959 ; BD stands for the DNA-binding domain of Gal4). The PstI fragment was then deleted to express BD-Cream1p (containing residues 1-455). The EcoRI fragment of cDNA clone Ap-2 was introduced into pY1 [23] to express BD-Ap2 (containing residues 463-959).
Plasmids for expression of other proteins in E. coli
To express full-length TFII-I tagged with hexahistidine (His6-TFII-I), the 3.4 kb NotI (treated with mung bean nuclease)-BamHI restriction fragment from pI3-CX (kindly provided by Dr. R. G. Roeder, Rockefeller University, New York, NY, U.S.A.) was ligated to pTrcHisA (Invitrogen) linearized with NheI (filled in with Klenow enzyme) and BamHI. The predicted construct, pHisII-I, was identified by both restriction digestion and Western analysis. To express FLAG-E2F1 (containing residues 123-437), the 1.1 kb BamHI-EcoRI fragment from pGST-SH5 [18] was ligated into pFLAG1 (IBI) digested with BglII and XhoI ; both the EcoRI and XhoI termini were filled in with Klenow enzyme before ligation. To express FLAGmitosin10N, the 1.3 kb EcoRI-HindIII (filled in with Klenow enzyme) restriction fragment from pMBP-10\H [22] was cloned between EcoRI and SalI (filled in with Klenow enzyme) of pFLAG1 to create pF10N. To express His6-p56Rb, pGEX-2T-RBS, which expresses a functional 56 kDa form of Rb [1] , was cleaved with BamHI and EcoRI. The cDNA insert was then introduced into pTrcHisA cleaved in the same way to create pTrcHisA-RBS. pGEX-2T-RBS was provided by Dr. W.-H. Lee (University of Texas Health Science Center at San Antonio, San Antonio, TX, U.S.A.).
Antibody production
The 0.5 kb EcoRI-A aI (partly cleaved and filled in with Klenow enzyme) restriction fragment of Ap-2, containing nt 1394-1925, was inserted into pMAL-c vector (New England Biolabs) cleaved with PstI (treated with mung bean nuclease) and EcoRI. The resulting plasmid, pMAL-P05, was used to express maltosebinding protein (MBP) fusion protein MBP-P05. After affinity purification with amylose resin (New England Biolabs), the fusion protein was cleaved with Factor Xa (New England Biolabs). The immunogen (P05) was blotted to Westran PVDF membrane (Schleicher & Schuell) after SDS\PAGE [12 % (w\v) gel]. The immunogen-containing portion was excised and used to immunize rabbits, as described [24] . In some cases, specific antibodies were further purified from antisera by using MBP-P05 immobilized on Hybond-C membrane (Amersham), as described [25] .
Rb-binding assay in vitro
FLAG-tagged or His-tagged fusion proteins were expressed as described previously [22] , with E. coli strain BL21 as host. His6-p56Rb was purified with TALON metal-affinity resin (Clontech) and eluted with 100 mM of EDTA (pH 8.0). Bacterial lysates containing FLAG-Cream1p, FLAG-Ap32, FLAGmitosin10N and FLAG-E2F1 were subjected to SDS\PAGE [8 % (w\v) gel] followed by electroblotting to Optitran BA-S membranes (Schleicher & Schuell). The Rb-binding assay was performed in itro as described previously [18] with minor modifications. The Rb sandwich was prepared by mixing 1 µg of His6-p56Rb, 1 µl of anti-hexahistidine monoclonal antibody Novel retinoblastoma protein-associated nuclear protein (mAb) (Sigma) and 1 µl of alkaline phosphatase-conjugated goat anti-mouse IgG (Promega) into each 1 ml of binding buffer. Results were detected with CDP-Star chemiluminescent substrate (Promega).
Cell culture and transfection
Normal monkey kidney CV1, human gastric carcinoma SGC-7901, human lung adenocarcinoma SPC-A1 and human ovarian carcinoma HO-8901 cells were maintained in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10 % (v\v) calf serum (Sijiqin Company, Hangzhou, China) in an air\CO # (19 : 1) atmosphere. Transfection was performed by the conventional calcium phosphate method.
Co-immunoprecipitation, immunoblotting and indrect immunofluorescence (IIF) studies
Approx. 2i10( CV1 cells co-transfected with pFCream1 and pCepRB (provided by Dr. W.-H. Lee) (1 : 1) were lysed in 1 ml of buffer A [20 mM Tris\HCl (pH 7.5)\100 mM KCl\0.1 % (v\v) Nonidet P40\1 mM EDTA\1 mM dithiothreitol\10 % (v\v) glycerol\50 mM NaF plus protease inhibitors]. After the removal of cell debris by centrifugation, half of the lysate was incubated overnight with 5 µg of anti-Rb mAb 3C8 (provided by Dr. W.-H. Lee) at 4 mC ; another half with the same amount of anti-CD4 mAb (Dako). Protein A-Sepharose (25 µl) (Pharmacia) preincubated with 10 µg of rabbit antimouse IgG (Anogen) was added for a further 2 h. The beads were then washed with 1 ml of buffer B [20 mM Tris\HCl (pH 7.5)\150 mM KCl\0.5 % (v\v) Nonidet P40\1 mM EDTA\1 mM dithiothreitol\10 % (v\v) glycerol\50 mM NaF plus protease inhibitors] three times. Samples were then subjected to SDS\PAGE [8 % (w\v) gel] and immunoblotting.
Immunoblotting and IIF microscopy were performed as described previously [22] , with appropriate primary antibodies. Enzyme-conjugated secondary antibodies were purchased from Promega. FITC-conjugated secondary antibodies were from Sino-America Biotechnology Company (Shanghai, China). Anti-FLAG M2 and anti-hexahistidine mAbs were from Kodak and Sigma respectively. In competition experiments, primary antibodies were incubated with 5 µg of MBP-P05 or MBP for 30 min before immunoblotting or IIF staining. IIF images were recorded on Kodak Gold III (ASA 400) film with an Olympus BX50 fluorescence microscope. Prints and other results were digitized with a U-Max vista-S6 scanner. Images for publication were organized with Adobe Photoshop software and exported from a Tektronix Phaser 450 image printer.
Yeast transformation and assay for β-galactosidase activity
We followed the protocols given by Clontech. Yeast strain Y190 (Clontech) was transformed with appropriate plasmids by using the lithium acetate method. Transformants were selected for their ability to grow on synthetic drop-out medium lacking tryptophan (SD\kTrp). β-Galactosidase activities were quantified by o-nitro-β--galactopyranoside assays of randomly picked colonies.
RESULTS
Cream1 is a novel protein related to TFII-I
The deduced amino acid sequence from clone Ap-2 ( Figure 1 ) suggests a novel polypeptide with three conserved repeats of 86 residues each. We therefore named the corresponding full-length protein Cream1 (for containing repetitive eighty-six amino-acid motif). Because Northern blotting indicated a ubiquitously expressed mRNA of approx. 3 kb (results not shown), a retinoblastoma Y79 cDNA library was screened with $#P-labelled Ap-2 as a probe. The two longest clones, S21 (2.2 kb) and S22 (2.2 kb), were studied further ( Figure 1A ). Sequence analysis revealed that clone S21 contained a deletion of nt 1974-2018 that nevertheless did not disrupt the reading frame (results not shown), possibly owing to alternative splicing. Clone S22, in contrast, lacked a G base at position 1406, resulting in a shift in reading frame. Further screening with several other cDNA libraries did not result in longer fragments. We therefore used a PCR approach to exhaust a human placenta cDNA library (Clontech) by using one primer fixed on the vector and another primer located in the 5h region of S22. It seemed that the longest PCR product (B18, 0.6 kb) still lacked some coding sequences of approx. 200 bp in comparison with the expressed sequence tag (EST) sequence of mouse clone 555547 (GenBank accession no. AA111609 ; 483 bp). This EST probably represented the extreme 5h sequence of the murine counterpart owing to the existence of two stop codons upstream of the putative first methionine residue (results not shown). Then a 320-bp PCR fragment (clone A1) was obtained with Marathon cDNA from human fetal spleen (Clontech) as templates ( Figure 1A remaining nucleotides from clone Ap-2. All these fragments had been sequenced to exclude unexpected sequence changes.
Cream1 shared distinct similarity with the multifunctional transcription regulator TFII-I (also named BAP-135 and SPIN) ( Figure 2) [10, 11, 15] . First, Cream1 contained a group of five conserved repeats, Cr1-Cr5, which were similar to the six repeats of TFII-I, Tr1-Tr6 (Figures 2A and 2B ). In fact, only an 80-residue region within each repeat (underlined in Figure 2B ) was conserved between both proteins. Secondly, the N-terminal portion of Cream1, residues 30 to 88 [i.e. conserved region 1 (Ccr1)], was also highly homologous to the corresponding Tcr1 from TFII-I, residues 22-80 ( Figures 2A and 2C) ; both Ccr1 and Tcr1 contained a conserved hydrophobic zipper-like motif implicated in protein-protein interaction ( Figure 2C ) [10] . Moreover, Ccr2 (residues 499-510) and Ccr3 (residues 527-532) also had their counterparts, Tcr2 (residues 801-812) and Tcr3 (residues 224-229) respectively, in TFII-I (Figures 2A and 2C) . On the basis of these similarities, both proteins apparently belonged to a novel protein family. Nevertheless, Cream1 also possessed other unique features. Among them were a tract of 12 serine residues (residues 912-923) and a putative nuclear localization signal (NLS) (residues 898-905 ; Figure 1B ). This NLS closely resembled that of the large T antigen of SV40 [26] .
Interestingly, a cDNA coding for a novel muscle-enhancerbinding protein, MusTRD1 [27] , has emerged as being basically identical with Cream1 cDNA. However, MusTRD1 is only 458 residues long, mainly due to a reading frame shift : there is an extra G base insertion within the region equivalent to 1307-1309 of Cream1 cDNA. MusTRD1 therefore contains only the first two repeats of Cream1. On the basis of sequence analyses of clone S21, clone S22 and all the available ESTs, none of the clones contained the G insertion characteristic of MusTRD1 cDNA (results not shown). This difference in MusTRD1 could be due to a specific form of mRNA in muscles, although we cannot at present exclude the possibility of a mutation or a sequencing artifact.
Gene structure and locus
We also determined the complete gene structure for Cream1 ( Figure 2D ). The structural gene, CREAM1, was found to lie in genomic clones DJ0665P05 (approx. 133 kb ; GenBank accession AC004851) and DJ1186P10 (approx. 149 kb ; GenBank accession AC005231). Both clones were sequenced to near completion and released to GenBank by Dr. R. H. Waterston (Genome Sequencing Center, Washington University School of Medicine, St. Louis, MO, U.S.A.). CREAM1 was located in four separate contigs and the lengths of gaps between these contigs were at that time unknown. This gene was composed of 27 exons spanning at least 150 kb ( Figure 2D and Table 1 ). Exon 2 contained the first ATG codon and, together with exon 3, encoded the hydrophobic zipper-like region Tcr1. Coding sequences for the conserved regions Ccr2 and Ccr3 resided in exons 13 and 14 respectively. In addition, each Cream1 repeat Novel retinoblastoma protein-associated nuclear protein was encoded by three adjacent exons. For instance, Cr1 was encoded by exons 4-6, Cr2 by exons 8-10, Cr3 by exons 16-18, Cr4 by exons 20-22 and Cr5 by exons 23-25. In each set of three exons, the length of the middle one was fixed to 184 bp except for exon 24, which was 193 bp ( Figure 2D and Table 1 ). Cream1 cDNA corresponds to human UniGene Hs.21075. The corresponding gene has been mapped to human chromosome 7q11.23 in the GeneMap'98 issued at the NIH web site (http :\\www.ncbi.nlm.nih.gov). The sequence-tagged site (sts-AA019591) used to map CREAM1 lay partly in the intron between exons 26 and 27 and extended further into exon 27 (results not shown). Interestingly, the CREAM1 locus was sandwiched between the genes for LIM-kinase and xyntaxin 1A in GeneMap'98. The frequent deletion of these two genes in Williams' syndrome [28, 29] suggests that CREAM1 is also deleted in the disease.
Cream1 is a ubiquitously expressed protein of 120 kDa
To explore the biochemical properties of Cream1, we generated rabbit polyclonal antibodies by using bacterially expressed polypeptide antigen (P05) containing residues 463-640. An MBP fusion (MBP-P05) of approx. 70 kDa was expressed ( Figure 3A , lane 1). After treatment with Factor Xa, MBP-P05 was cleaved into two portions : MBP alone (approx. 40 kDa) and P05 ( Figure  3A, lane 2) . P05 appeared as a doublet of approx. 30 and 31 kDa, possibly owing to one or more alternative cleavage sites of Factor Xa or to degradation. Because the cDNA insertion did not disrupt the reading frame of the LacZα gene designed for α- complementation in the vector pMAL-c (New England Biolabs), P05 also contained a portion of β-galactosidase (approx. 60 residues). As shown in Figure 3(A) , preimmune serum did not detect any proteins (lane 3). The immune serum specifically recognized both the doublet of P05 and the trace amount of intact MBP-P05, but not MBP despite its high abundance ( Figure 3A, lane 4) .
Because P05 contained both the third repeat and two additional regions homologous with TFII-I (Figures 1 and 2) , we examined whether the antibody could cross-react with TFII-I. As shown in Figure 3(B) , the Cream1 mutant FLAG-Ap32 was specifically detected as a protein of approx. 90 kDa in total bacterial lysate by either the anti-Cream1 polyclonal antibody T8 (lane 1) or anti-FLAG M2 mAb (lane 5). However, neither of these two antibodies recognized the full-length hexahistidine-tagged TFII-I (His6-TFII-I) ( Figure 3B, lanes 2 and 6) . In contrast, antihexahistidine mAb faithfully detected this TFII-I as a 120 kDa protein ( Figure 3B, lane 4) . These results indicate that the antiCream1 antibody T8 was highly specific.
This antibody was then used to detect endogenous Cream1 in African green monkey CV1 cells (Figure 4) . It recognized both MBP-P05 in bacterial lysate ( Figure 4A , lane 1) and a protein of approx. 120 kDa in CV1 total cell lysate (lane 2). To examine whether this 120 kDa protein was Cream1, the antibody was preincubated with either MBP-P05 or MBP expressed from pMAL-c vector. The antibody neutralized by MBP-P05 failed to detect either MBP-P05 ( Figure 4A, lane 3) or the 120 kDa protein (lane 4). However, preincubation with MBP had no effect on the antibody ( Figure 4A, lanes 5 and 6) . These results indicated that Cream1 in CV1 cells migrated as a protein of approx. 120 kDa on SDS\PAGE. In addition, the same protein was also detected in a variety of human cell lines and tissues, including embryonic kidney HEK 293, gastric carcinoma SGC-7901, lung adenocarcinoma SPC-A1, ovarian carcinoma HO-8901, fetal and adult skeletal muscles, heart and fetal brain (results not shown). Generally, the protein levels in all the tested samples were quite low.
To examine whether the Cream1 cDNA contained the entire open reading frame, we also compared the migration rates of the cellular Cream1 and FLAG-tagged full-length Cream1 (FLAGCream1) expressed in E. coli ( Figure 4B ). FLAG-Cream1 ( Figure  4B , lane 2) migrated closely to and a little more slowly than endogenous Cream1 in CV1 cells (lane 1) owing to the existence of the FLAG tag. These results confirmed that our cDNA contained the complete coding sequence for Cream1.
Cream1 binds to Rb both in vitro and in vivo
Cream1 was isolated as a candidate of Rb-associated proteins that was previously named Rbap2 [18] . To confirm the screening results, we tested its interaction with Rb in a similar assay. For convenience we used affinity-purified hexahistidine-tagged Rb (His6-p56Rb) to prepare the ' Rb sandwich ' (Figure 5A ). FLAG-mitosin10N, which contained residues 2484-2927 of mitosin ( Figure 5B, lane 1) , served as a negative control ( Figure  5C , lane 1) [22] . FLAG-E2F1, which contained residues 123-437 ( Figure 5B, lane 3) , was used as a positive control ( Figure 5C , lane 3) [18] . Two overlapping deletion mutants of Cream1, FLAG-Cream1p and FLAG-Ap32, were tested ( Figure 5D ). Figure 5C, lane 2) . However, FLAG-Cream1p ( Figure  5B , lane 4) was negative ( Figure 5C, lane 4) . Because the 
Figure 8 Schematic diagrams for BD-Cream1 fusion proteins
The transactivation activities of these constructs are shown in Table 2 .
polypeptide encoded by clone Ap-2 spanned residues 463-959, these results confirmed that Rb specifically interacted with this C-terminal portion of Cream1 in itro.
Owing to low levels of endogenous Cream1, we co-expressed FLAG-Cream1 and Rb in CV1 cells to boost the local concentrations of these two proteins. The proper expression of FLAGCream1 was monitored by IIF staining (results not shown). When the lysate from these cells was subjected to co-immunoprecipitation with anti-Rb mAb ( Figure 6 , lane 1), FLAGCream1 was readily detected with anti-FLAG1 mAb M2 in multiple experiments (lane 3). In contrast, a control antibody (anti-CD4 mAb) failed to pull down either Rb ( Figure 6, lane 2) or Cream1 (lane 4). However, reciprocal experiments were not successful because for some reason neither anti-Cream1 nor anti- Yeast cells (strain Y190) transformed with indicated plasmids were subjected to assays with o-nitro-β-D-galactopyranoside. The β-galactosidase activity (1 unit l amount of enzyme hydrolysing 1 µmol substrate/min per cell) for each transformation is presented as the meanpS.D. for three randomly picked colonies. pAS2-1 and pY1 were control plasmids that expressed only BD. See Figure 8 for diagrams of the fusion proteins encoded by these plasmids. 
NLS of Cream1 resembles that of the large T antigen of SV40
As a potential transcription regulator, Cream1 should be a nuclear protein. Nuclear localization is also essential for interaction with Rb. On the basis of the amino acid sequence, Cream1 contained a putative NLS similar to that of the large T antigen of SV40 ( Figure 1B ). However, cellular Cream1 was not detected by IIF microscopy in cell lines including CV1, HEK 293, SGC-7901, SPC-A1 and HO-8901 (results not shown), in agreement with the low expression levels implied by immunoblotting results ( Figure 4 , and results not shown). We then transiently expressed FLAG-Ap32 ( Figure 7A ) into CV1 cells. Indeed, FLAG-Ap32 exhibited typical nuclear localization when detected with both anti-FLAG antibody ( Figure 7B , panel 1) and the anti-Cream1 antibody T8 (panel 2). To exclude a possible cross-reaction between antibodies during the labelling process, MBP-P05 was added to the mixture of primary antibodies to neutralize anti-Cream1 antibody selectively. This treatment did indeed significantly decrease the labelling by anti-Cream1 antibody T8 ( Figure 7B , panel 4) without disturbing that by anti-FLAG antibody (panel 3), indicating that these two antibodies recognized their own epitopes independently. Nuclear localization was also observed when the full-length FLAG-Cream1 was expressed (results not shown). When the putative NLS was deleted, the corresponding mutant, FLAG-Ap32N ( Figure 7A ), became totally cytoplasmic ( Figure 7B , panels 5 and 6), suggesting that Cream1 did indeed use the sequence as the NLS.
Cream1 has an intrinsic activating activity
To examine whether Cream1 contains an activation domain, we fused different portions of Cream1 with BD (DNA-binding domain of Gal4) and investigated the trans-activation activities of the resulting molecules in yeast. Yeast strain Y190 contains a reporter gene for β-galactosidase under the control of a Gal4-responsive promoter. As shown in Figure 8 and Table 2 , the expression of BD-Cream1 in Y190 did indeed strongly stimulate the transcription of the reporter gene as judged by β-galactosidase activities. BD-Cream1p, which contained residues 1-455 of Cream1, was still active. In contrast, the fusion protein containing residues 463-959, i.e. BD-Ap2, showed little trans-activation activity over the background. An activation domain therefore seemed to reside in the N-terminal half of Cream1.
DISCUSSION
Cream1 and TFII-I are distinct members of a novel transcription regulator family
The 80-residue repeats and other conserved regions shared by Cream1 and TFII-I suggest that these two proteins fall into a novel protein family, possibly the TFII-I family. MusTRD1 [27] probably resulted from an alternatively spliced mRNA transcribed from CREAM1, although its existence still requires further investigation. TFII-I binds to a variety of DNA sequences including initiator and initiator-like (SIE and serum-responsive element) sites, and the E-box element [10] [11] [12] . It is important for the transcription regulation of several cellular genes, including c-fos and T-cell receptor [12, 14] . MusTRD1, in contrast, reportedly binds to an enhancer element (USE B1) that is similar to SIE, with binding site requirements distinct from that of TFII-I [27] . From the sequence identity, Cream1 would also be a potential binding protein for USE B1. The structural genes of TFII-I (i.e. GTF2I) [17] and Cream1 (i.e. CREAM1) were related. Both gene loci were close together at human chromosome 7q11.23 according to GeneMap '98. Exon organizations were also similar : when multiple exons were required to encode a conserved region, their junctions were usually conserved in both genes. This was true for the junctions within sequences coding for Ccr1 and Tcr1, and all of the first junctions and most of the second junctions within sequences coding for Cr1-5 and Tcr1-6 ( Figure 2D and Table 1 ) [17] . In addition, each of the sequences coding for Ccr2, Ccr3, Tcr2 and Tcr3 was located within one short exon. Evidently the positions of these exons were subjected to independent rearrangements (exon shuffling) during the evolution of CREAM1 and GTF2I, resulting in altered locations of Ccr2 and 3 in contrast with Tcr2 and 3 ( Figure 2 ) [17] .
Potential function of Cream1
Cream1 is expressed ubiquitously as a 120 kDa protein in cell lines and tissues of various origins ( Figure 4 , and results not shown). Its structural similarity to TFII-I further suggests itself to be a general transcription regulator, possibly a novel initiatorbinding factor to mediate the transcription of certain TATA-less promoters. However, its identity with MusTRD1 also implies a function in slow muscle fibres [27] . To our surprise, the levels of Cream1 in skeletal muscles, including muscle samples from fetus and adults, were very low (results not shown). Such results were contradictory to the specific expression of the MusTRD1 gene (CREAM1) in skeletal muscles [27] . One possibility is that the halflife of Cream1 in muscles could be short. The steady-state levels of the protein were therefore low, despite high levels of synthesis. Another explanation could be that the major isoform in muscles is MusTRD1 instead of Cream1. After all, the extra G base that results in premature termination of the coding sequence in MusTRD1 cDNA could be due to alternative splicing because it lay at the junction between exons 10 and 11 of CREAM1 ( Figure 2 and Table 1 ) [27] . This explanation, however, still depends on the further characterization of MusTRD1 because no protein data for it are yet available to support the existence of such an isoform.
Both MusTRD1 and Cream1 might serve as positive transcription regulators. MusTRD1 cDNA was cloned by using the yeast one-hybrid system via its binding to USE B1, a regulatory DNA element located in the enhancer of slow-muscle-fibrespecific troponin I (TnI S ) promoter [27] . Moreover, Cream1 fused to BD was able to stimulate reporter gene transcription in the yeast system, indicating the existence of an activation domain in the region shared by both MusTRD1 and Cream1. In contrast, our study showed that MusTRD1 lacks a valid NLS (Figure 7) . A FLAG-tagged polypeptide resembling MusTRD1 also failed to enter the nucleus (results not shown). Consequently, Mus-TRD1, if it exists, has to find other ways in which to enter the nucleus. The relationship between these two proteins apparently still needs further investigation.
Regulation of Cream1 and TFII-I
The functions of Cream1 and TFII-I might be regulated by distinct mechanisms. TFII-I (i.e. BAP-135) binds to Btk, a B-cellspecific cytoplasmic tyrosine kinase of the Src superfamily [15] . On engagement of B-cell antigen receptors, TFII-I is transiently phosphorylated on tyrosine residues. Moreover, the stimulation of c-fos promoter by TFII-I depends on Ras-signalling pathways [14] . The Src-autophosphorylation sites of TFII-I are critical for the TFII-I-dependent transcription activation of Vβ promoter [16] . In contrast, Cream1 apparently lacked the Src-phosphorylation sites ; neither did it interact with Btk in our hands (results not shown). Nevertheless, it could be regulated by MAP kinase through a potential phosphorylation site (Figure 1 ). In addition, our results suggest that Cream1 might be regulated through association with Rb. On the basis of its broad expression spectrum, Cream1 might act as a general transcription regulator involved in cell-cycle progression. However, Rb is also essential to terminal differentiation of skeletal muscles [6, 7] . Depending on the function of MusTRD1 [27] , Cream1 might have a role in muscle differentiation under the control of Rb.
Hemizygosity of CREAM1 might contribute to Williams' syndrome
Williams' syndrome is a congenital disorder with characteristic elfin-like facial features and mental retardation, which is frequently associated with cardiovascular and musculoskeletal problems and many other traits [30, 31] . Hemizygosity at chromosome 7q11.23 is responsible for the condition [30] . The breakpoints of common deletions are located approx. 1 cM on each side of the gene for elastin [32] . So far, almost a dozen genes have been reported to be hemizygous in most Williams ' populations. Among them are genes for elastin [30] , LIM kinase 1 [28] , replication factor C [33] , the human counterpart of the Drosophila frizzled Wnt receptor [34] , syntaxin 1A [29] , TFII-I [17] , Wscr1 [35] and Fkbp6 [36] . Although a sufficient dose of LIM-kinase, a protein kinase mainly expressed in the brain, seems to be critical for the disease [28] , the rest of these genes might also contribute to the pathogenesis of this syndrome.
Owing to its location between genes coding for LIM kinase 1 and syntaxin 1A in GeneMap'98, we speculated that one copy of CREAM1 might also be deleted from the genotype of all people with Williams ' syndrome hemizygous for these two genes. This speculation has been confirmed by the delineation of a gene, WBSCR11, in the region commonly deleted in Williams ' syndrome [37] . WBSCR11, whose gene structure is also identified from the same genomic clones as we did for CREAM1, is apparently identical with CREAM1. However, the deduced amino acid sequence from the reported WBSCR11 cDNA lacks some sequences encoded by exon 19 of CREAM1, a situation also found in cDNA clone S21 ( Figure 1A ). Both cDNA species therefore represent different mRNA isoforms of the same gene.
Owing to the expression of Cream1 in brain (results not shown), its decreased dose might affect the expression of one or more other proteins important for neuronal development. In contrast, TnI S predominates in all muscle types during early fetal development and is restricted to both the slow muscle fibres and
